Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
46.87
+0.02 (0.03%)
Apr 23, 2026, 10:26 AM EDT - Market open
Exelixis Employees
Exelixis had 1,077 employees as of December 31, 2025. The number of employees decreased by 70 or -6.10% compared to the previous year.
Employees
1,077
Change (1Y)
-70
Growth (1Y)
-6.10%
Revenue / Employee
$2,154,249
Profits / Employee
$726,620
Market Cap
11.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,077 | -70 | -6.10% |
| Dec 31, 2024 | 1,147 | -163 | -12.44% |
| Dec 31, 2023 | 1,310 | 87 | 7.11% |
| Dec 31, 2022 | 1,223 | 269 | 28.20% |
| Dec 31, 2021 | 954 | 181 | 23.42% |
| Dec 31, 2020 | 773 | 156 | 25.28% |
| Dec 31, 2019 | 617 | 133 | 27.48% |
| Dec 31, 2018 | 484 | 112 | 30.11% |
| Dec 31, 2017 | 372 | 85 | 29.62% |
| Dec 31, 2016 | 287 | 172 | 149.57% |
| Dec 31, 2015 | 115 | 17 | 17.35% |
| Dec 31, 2014 | 98 | -129 | -56.83% |
| Dec 31, 2013 | 227 | 53 | 30.46% |
| Dec 31, 2012 | 174 | -26 | -13.00% |
| Dec 31, 2011 | 200 | -183 | -47.78% |
| Dec 31, 2010 | 383 | -293 | -43.34% |
| Dec 31, 2009 | 676 | 0 | - |
| Dec 31, 2008 | 676 | -59 | -8.03% |
| Dec 31, 2007 | 735 | 84 | 12.90% |
| Dec 31, 2006 | 651 | 101 | 18.36% |
| Dec 31, 2005 | 550 | 33 | 6.38% |
| Dec 31, 2004 | 517 | -56 | -9.77% |
| Dec 31, 2003 | 573 | 23 | 4.18% |
| Dec 31, 2002 | 550 | -21 | -3.68% |
| Dec 31, 2001 | 571 | 214 | 59.94% |
| Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Axsome Therapeutics | 925 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
EXEL News
- 1 day ago - Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - Business Wire
- 2 months ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March - Business Wire
- 2 months ago - Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 2 months ago - Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer - Business Wire
- 3 months ago - Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 - Business Wire
- 3 months ago - Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 - Business Wire
- 3 months ago - Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Business Wire
- 3 months ago - Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - Business Wire